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Abstract Lipoprotein lipase (LPL) is crucial in the hydroly-
sis of triglycerides (TG) in TG-rich lipoproteins in the for-
mation of HDL particles. As both these lipoproteins play an
important role in the pathogenesis of atherosclerotic vascu-
lar disease, we sought to assess the relationship between
post-heparin LPL (PH-LPL) activity and lipids and lipopro-
teins in a large, well-defined cohort of Dutch males with cor-
onary artery disease (CAD). These subjects were drawn
from the REGRESS study, totaled 730 in number and were
evaluated against 75 healthy, normolipidemic male controls.
Fasting mean PH-LPL activity in the CAD subjects was 108








0.0001). When these patients were divided into activity
quartiles, those in the lowest versus the highest quartile had
















0.001). Conversely, levels of TC, LDL, and HDLc were

























respectively). Also, in this cohort PH-LPL relationships with
lipids and lipoproteins were not altered by apoE genotypes.
The frequency of common mutations in the LPL gene asso-
ciated with partial LPL deficiency (N291S and D9N carri-
ers) in the lowest quartile for LPL activity was more than









 0.006). By contrast, the frequency of the S447X








0.006) in the highest quartile.  This study, in a large co-









 0.001) when compared to controls; that
the D9N and N291S, and S447X LPL variants are genetic
determinants, respectively, in CAD patients of low and high
LPL PH-LPL activities; and that PH-LPL activity is strongly
associated with changes in lipids and lipoproteins.—
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The role of lipoprotein lipase (LPL) in the modulation
and determination of plasma lipid and lipoprotein levels
is now well recognized. This is particularly evident in indi-
viduals who have a genetic deficiency of LPL (Type 1 hy-
perlipoproteinemia) and present with markedly elevated
chylomicron levels and decreased VLDL, LDL, and HDLc
concentrations. Individuals heterozygous for these null
genetic defects, with approximately 50% activity, often
also show abnormal lipid and lipoprotein levels in fasting
plasma (1–5). Variations of LPL activity in normal subjects
are likewise known to influence plasma lipids. This is par-
ticularly evident for HDLc, where studies in healthy adults
(6–9), twins (10), and dyslipidemic patients (11–13) have
shown a statistically significant positive correlation with
fasting post-heparin plasma LPL (PH-LPL) levels. This
finding is in keeping with the hydrolytic action of LPL on
triglyceride in the triglyceride-rich lipoproteins and with
the entry of the excess surface phospholipid, cholesterol,
and apolipoproteins into the HDL pool. The relationship
of PH-LPL to fasting plasma TG levels is less clear, as the
findings of a negative correlation in healthy adults (6, 14–
16), dyslipidemic, obese and diabetic subjects (16–19),
has not been substantiated in other studies (20–24).
 
Abbreviations: LPL, lipoprotein lipase; TG, triglycerides; PH, post-
heparin; CAD, coronary artery disease; HDL, high density lipopro-
teins; LDL, low density lipoproteins; DGGE, density gradient gel elec-




To whom correspondence should be addressed.















Significant difficulties in the assessment of some of
these studies have been the small numbers of subjects and
the resulting low discriminatory power, the presence of
mixed genders, and the measurement of LPL activity in
different laboratories, with differing assay methods. Here
we have re-examined this question in a large single-gender
cohort, comprising 730 Dutch males with angiographi-
cally defined coronary artery disease. Further design fea-
tures of significance and relevance were the assay of PH-
LPL levels in one laboratory using a single assay procedure
and a rigorously controlled protocol of heparin injection
and blood withdrawal for LPL determination.
Here we demonstrate that PH-LPL levels are lower in
CAD subjects when compared to normolipidemic controls
with a 22% decrease in the mean activity level. We further
demonstrate unequivocally that PH-LPL activity in male
CAD patients correlates inversely with fasting plasma TG
and directly with HDLc levels. These correlations are in
keeping with the role of LPL in the lipolysis of lipoprotein
triglyceride and the generation of HDL particles. Also, the
apoE genotype in these subjects was found to be of minor
significance in determining the relationships between PH-
LPL levels, with lipids and lipoproteins.
We, and others, have previously shown that the D9N
and N291S variants in the LPL gene are associated both in
vitro and in vivo, with lowered catalytic activity (16, 25–
28). We, therefore, determined the frequency of these
variants in our CAD cohort and demonstrate that carrier
status for these variants is a genetic determinant of low
PH-LPL in CAD patients. The joint frequency of these
variants in patients in the lowest quartile of PH-LPL levels
was more than double that of the frequency in subjects in
the highest quartile. Conversely, we demonstrate that the
S447X gene variant is a likely contributory factor to the de-
termination of PH-LPL levels in those subjects in the upper
quartile of LPL activities.
Collectively these data from the REGRESS study suggest






Post-heparin plasma LPL activity measurements were available
from 730 of the 885 subjects in the REGRESS study (29) which
was designed as a double-blind, placebo-controlled, multi-center
study to assess the effect of pravastatin treatment on the progres-
sion and regression of coronary atherosclerosis. No selection bias
was evident for the 730 individuals examined. All patients were
males of Caucasian descent, below 70 years of age, and had an-





sis of a major vessel). Patients were specifically excluded who had
unstable angina or who suffered a myocardial infarction within
the preceding 6 months. All patients had to have total choles-






 75) were drawn from the general population,
and were healthy, normolipidemic males, off lipid-lowering medi-
cation, and between 25 and 55 years of age with a mean age of 46
(5.1) years. All patients participating in the REGRESS trial signed
written informed consent and the study protocol was approved
by all institutional review boards of all respective hospitals.
 
Lipid and lipoprotein analysis
 
All laboratory tests were carried out at the Lipid Reference
Laboratory, Academic Center, Amsterdam. Serum cholesterol,
HDL cholesterol, and triglycerides were measured on fasting
blood samples by standard methodologies (29). LDL cholesterol
was calculated according to the Friedewald formula (30). The
Lipid Reference Laboratory is an international member of the
USA National Cholesterol Reference Method Laboratory Net-





In a search for LPL mutations associated with lowered catalytic
activity, DNA from all patients in the lowest quartile of LPL activ-
ity was subjected to mutation analysis by PCR and density gradi-
ent gel electrophoresis (DGGE), with sequencing, where indi-









and the translated sequence of exons 1–10 of the LPL gene. The





. In addition, the entire subject cohort was
screened for the Asp9Asn (D9N), Asn291Ser (N291S), and
Ser447Stop (S447X) mutations in the LPL gene. This was
achieved by PCR and restriction endonuclease digestion of am-
plified product, as described previously (16, 31, 32).
ApoE genotypes were determined by PCR and digestion with
the restriction endonuclease Hha1 as described (33).
 
Post-heparin plasma lipase activity
 
Lipase activities were obtained on enrollment and were deter-
mined in fasting plasma, separated from blood collected after IV
heparin (50 IU/kg). Patients were kept sedentary for 20 min af-
ter which heparin was injected as a bolus in normal saline. Twenty
min later blood was drawn from the alternate arm and immedi-
ately placed on wet ice for transport to the central laboratory. All
samples were received within 6 h of collection. LPL was deter-
mined after inhibition of hepatic lipase (HL) by co-incubation





H]trioleoylglycerol as substrate. Released
fatty acids were extracted as calcium salts and counted in a liquid
scintillation counter.
The number of subjects in this cohort was large enough to al-
low for subdivision into groupings of varying LPL levels, which
increased the comparative value of the study. Subjects were
therefore partitioned into quartiles of PH-LPL activities. Follow-
ing current convention, quartiles 2 and 3 were combined to give





The distribution of PH-LPL activity was checked for its shape
and was transformed by the Box-Cox method for stabilization
and normalization. The association between PH-LPL activity and
baseline patient characteristics was assessed using ANOVA,
univariate and multiple regression analysis. The frequency of mu-
tations in different quartiles of LPL activity was tested using a






PH-LPL levels were determined in 730 patients. The




 8.1 years; whereas 73%
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-blockers and 87% reported a past





































 0.22), and systolic or
































 0.97, respectively). Other characteristics, notably
CAD risk factors, CAD-related parameters, or pharmaco-
logical treatment, did not differ among patients in the
lowest, intermediate, or highest quartiles of LPL activity
(Table 2).
 
LPL-activity and lipid levels
 





 46) with values ranging from 13 to 293 mU/mL
and having a median of 103 mU/mL. The distribution of









 0.002). The maximum likelihood estimate of the
power parameter of the Box-Cox transformation was 0.4
with a 95% confidence interval (CI) of 0.32–0.56. Conse-




0.5) to normalize and standardize the LPL distribution. In
 
TABLE 1. Sets of flanking intronic primers for PCR and DDGE analysis
 




















































































































































































































Exon 9 59-(CG)20CCTGACAGAACTGTACCTTTGTGAACA-39 293
59-GAATGCATGAAGCTGCCTCCCTTAG-39














Age (yr) 55 (8) 57 (8) 57 (8) 56 (8) 0.11
Body mass index (kg/m2) 25.9 (2.8) 26.0 (2.8) 26.5 (2.9) 25.6 (2.3) 0.22
Systolic BP (mm Hg) 133 (19) 137 (20) 137 (20) 135 (17) 0.16
Diastolic BP (mm Hg) 81 (11) 82 (11) 81 (10) 82 (9) 0.97
Current smoking: n (%) 53 (28%) 54 (30%) 48 (27%) 42 (23%) 0.47
Insulin (U/L) 11.88 (9.51) 11.26 (7.29) 11.1 (7.73) 10.13 (6.55) 0.24
Glucose (mmol/L) 5.28 (1.35) 5.41 (1.33) 5.39 (1.47) 5.17 (1.17) 0.28
Fibrinogen (g/L)e 1.12 (0.41) 1.17 (0.39) 1.14 (0.38) 1.12 (0.39) 0.80
Medical treatment
Beta-blockers 144 (75%) 133 (74%) 139 (77%) 127 (71%) 0.62
Calcium channel blockers 124 (65%) 109 (61%) 109 (60%) 107 (59%) 0.72
ACE inhibitors 13 (7%) 15 (8%) 20 (11%) 19 (11%) 0.45
Pravastatin 86 (45%) 96 (53%) 100 (55%) 82 (48%) 0.19
Results are given as mean (SD) or number (SD) unless otherwise stated; BP, blood pressure; n, number of patients.
a Quartile 1: PH-LPL activity, <77 mU/ml.
b Quartile 2: PH-LPL activity, 78–103 mU/ml.
c Quartile 3: PH-LPL activity, 104–132 mU/ml.
d Quartile 4: PH-LPL activity, >133 mU/ml.
e Result reported on the logarithmic scale.
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addition, mean and median of the square-root distribu-
tion of LPL activity were almost equal (10.16 vs. 10.15)
and the Kolmorov-Smirnov test showed a P value of 0.58,
indicating Gaussian distribution. The square root of LPL
activity was subsequently used in all statistical inferences.
The percentage variance of TG and HDLc attributable to
PH-LPL is equal to the squares of their respective corre-
lations (reported in Table 4), and were found to be
(20.02)2 5 4% and (0.025)2 5 6.3%, respectively.
Last, we divided the 730 patients into quartiles of LPL
activity. The first quartile (PH-LPL, 13–77 mU/mL) con-
tained 191 patients. The second (78–103 mU/ml) and
third quartiles (104–132 mU/mL) contained 179 and 181
patients, respectively, and the fourth quartile (133–293
mU/mL) contained 179 patients (Table 2). The sample
size in the first quartile is not equal to that of the others as
the boundary between the first and second quartiles bi-
sected a large number of patients who yielded PH-LPL ac-
tivities of exactly 77 mU/ml. All these patients were there-
fore included in the first quartile.
Comparison of PH-LPL levels in REGRESS 
subjects and controls
PH-LPL activities were available for 75 normolipidemic
controls, with a mean level of 138 (44) mU/mL (Table 3).
CAD patients and controls had significantly different LPL
activities, 108 (46) versus 138 (44) mU/mL; P , 0.0001,
which indicates a decrease of 22% in CAD patients. Signif-
icance was still obtained (P 5 0.001) if the study subjects
were divided into those on or off beta-blockers, 106 (42)
(n 5 543) and 114 (53) mU/ml (n 5 188), respectively.
Lipids and lipoproteins in different
quartiles of LPL activity
Patients in the lowest versus the highest quartile of LPL
activity had higher levels of triglycerides {log transformed;
0.58 (0.43) vs. 0.35 (0.42) mmol/l, P , 0.0001} and higher
levels of both VLDL-cholesterol and VLDL-triglycerides,
and IDL-triglycerides {log transformed; 20.69 (0.84) vs.
21.26 (1.08) mmol/l, P 5 0.002; 20.09 (0.83) vs. 20.62
(0.93), P 5 0.002, respectively; 22.18 (0.83) vs. 22.49
(0.60), P 5 0.02} (Table 4). Conversely, levels of total cho-
lesterol {5.96 (0.85) vs. 6.15 (0.84) mmol/l, P 5 0.01}, LDL-
cholesterol {4.21 (0.80) vs. 4.43 (0.77) mmol/l, P 5 0.026}
and HDL-cholesterol {0.86 (0.26) vs. 1.02 (0.23) mmol/l,
P , 0.0001} were significantly lower in patients in the lowest
versus the highest quartile of LPL activity. IDL-cholesterol
{log transformed; 21.92 (0.84) vs. 22.08 (0.86) mmol/l,
P 5 0.42} levels, were not statistically different (Table 4).
PH-LPL activity correlated positively with LDL-choles-
terol (r 5 0.14; P 5 0.011) and HDL-cholesterol (r 5 0.25;
P , 0.0001), but just missed significance (r 5 0.13; P 5
0.059) for total cholesterol. Conversely, a significant but neg-
ative association was evident for PH-LPL activity and triglyc-
erides (r 5 20.20; P , 0.0001). Values for triglycerides, VLDL,
and IDL-triglycerides, were based on log-transformation,
with means 6 SD being given in the tables. Plots of PH-LPL
activity versus plasma triglyceride and HDL-cholesterol are
depicted in Fig. 1A and 1B, respectively.
ApoE genotypes
ApoE genotypes were available for 606 of the 730 sub-
jects in this study cohort; no bias was discernable in the as-
certainment of these genotypes. Statistically significant
associations between PH-LPL activities, and lipid and lipo-
protein levels were evident in each genotype grouping,
with significance in the E3/3 cohort (n 5 356) only being
very similar to that of the associations in the total subject
cohort. Here, significance was shown for PH-LPL and plas-
ma TG, TC, LDLc, and HDLc. Weaker associations were
found in the other genotype divisions with the combined
E2/2 1 E2/3 subjects failing to show significance between
PH-LPL activities and either TG or HDLc levels, but reach-









LPL activity 138 6 44 108 6 46 ,0.0001
Values given as mean 6 SD; LPL, lipoprotein lipase; CAD, coro-
nary artery disease.















TGe 0.58 (0.43) 0.53 (0.45) 0.48 (0.42) 0.35 (0.42) 20.20 ,0.0001
IDL-TGe 22.18 (0.83) 22.32 (0.66) 22.26 (0.67) 22.49 (0.60) 20.14 0.0467
VLDL-TGe 20.09 (0.83) 20.05 (0.94) 20.45 (1.01) 20.62 (0.93) 20.23 0.0003
TC 5.96 (0.85) 5.97 (0.84) 6.12 (0.87) 6.15 (0.84) 0.13 0.059
VLDL-Ce 20.69 (0.84) 20.78 (1.02) 21.03 (1.02) 21.26 (1.08) 20.22 0.0033
IDL-Ce 21.92 (0.84) 21.99 (0.77) 21.94 (0.76) 22.08 (0.86) 20.05 0.65
HDL-C 0.86 (0.26) 0.89 (0.21) 0.96 (0.23) 1.02 (0.23) 0.25 ,0.0001
LDL-C 4.21 (0.80) 4.23 (0.74) 4.38 (0.76) 4.43 (0.77) 0.14 0.0112
Results in mmol/l; n, number of patients.
a Quartile 1: lipoprotein lipase activity, <77 mU/ml plasma.
b Quartile 2: lipoprotein lipase activity, 78–103 mU/ml plasma.
c Quartile 3: lipoprotein lipase activity 104–132 mU/ml plasma.
d Quartile 4: lipoprotein lipase activity >133 mU/ml plasma.
e Log transformed values.
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ing significance for total and LDL cholesterol. The com-
bined E4/3 1 E4/4 subjects only gave significant associa-
tions between PH-LPL, and TG and HDLc.
Contribution of LPL gene mutations to lowered 
PH-LPL activity in REGRESS subjects
Functional variants of LPL have been shown to occur
relatively frequently in the general population (34). There-
fore, to determine the contribution of mutations in the
LPL gene to decreased PH-LPL activity, DNA samples of
the 191 CAD patients in the lowest quartile of activity (<77
mU/mL) were subjected to comprehensive mutation anal-
ysis of the promoter and exonic regions of the gene.
As anticipated, sequence changes were detected in ex-
ons 2, 6, and 7, which, respectively, represent the Asp9Asn
(D9N), Asn291Ser (N291S), and Ser447➝Stop (S447X)
amino acid substitutions, previously described (27, 35,
36). The 293T/G promoter mutation (37) was found in
this group, and in each case was linked with the D9N mu-
tation. No additional base substitutions were identified in
these subjects, other than the three known (35, 38) silent
base substitutions in exons 3 (G405➝A), 4 (G435➝A), and
8 (C1164➝A), which occurred at carrier frequencies of 7.5,
3.3, and 1.5%, respectively. Individuals in the other quar-
tiles were not subjected to detailed mutation analysis but
were screened for the D9N, N291S, and S447X mutations.
The distribution and frequency of carriers of these LPL
variants is given in Table 2. In the entire cohort we found
27 D9N and 37 N291S carriers. One of these patients car-
ried both amino acid substitutions. Carriers of the S447X
Fig. 1. (A) A plot of post-heparin plasma lipoprotein lipase (PH-LPL) activity versus plasma TGs and (B)
versus high density lipoprotein cholesterol (HDLc) for the 730 subjects from the REGRESS study. Solid lines
represent the estimated regression lines between PH-LPL activity and TG and HDLc, respectively. Dotted
lines indicate the 95% confidence interval around these regression lines.










740 Journal of Lipid Research Volume 40, 1999
allele totaled 118; 4 were homozygous, while 6 also carried
either a D9N or a N291S substitution. The total number
of compound heterozygotes detected was 7, and these in-
dividuals were excluded from the analysis. No carriers of
the predominant Caucasian mutation, Gly188Glu (G188E)
were detected in this cohort.
Frequencies for D9N, N291S, and S447X carriers dif-
fered significantly between the lowest and highest quar-
tiles of LPL activity. The combined frequency of D9N and
N291S carriers in the lowest quartile was more than dou-
ble the frequency in the highest quartile (12.0% vs. 5.0%:
P 5 0.006), while conversely in the high quartile the
S447X frequency rose to 18.3% (11.5% vs. 18.3%: P 5
0.006) as depicted in Table 5. These 447stop frequency
differentials are similar to those reported previously by us
for a smaller subgroup of the REGRESS cohort (32).
DISCUSSION
The determination of PH-LPL levels in subjects with
CAD, from the REGRESS study, provided a unique oppor-
tunity for a rigorous appraisal of PH-LPL levels, and the
relationships of these levels with circulating lipids and li-
poproteins, particularly as a large number of single gen-
der subjects were available together with a highly con-
trolled laboratory assay for PH-LPL activity.
To our knowledge, our study is the first to demonstrate
directly through lipase activity measurements, that males
with CAD have lower mean levels of PH-LPL than normal
controls. Earlier studies (39–41) have examined this as-
pect but have not been able to record differing mean LPL
activities; however, the numbers of subjects in the cohorts
examined, in each case, were low. A large number of our
study subjects were on beta-blockers, which have been sug-
gested to inhibit LPL activity (42, 43). However, even
when we excluded these individuals, a significant reduc-
tion in mean PH-LPL activity was obtained for the CAD
patients. Another potential factor of influence to be con-
sidered here would be that of advancing age where a
decrease in PH-LPL activity has been reported (44). How-
ever, the difference in the mean ages between the control
and CAD subjects was not a factor in our study as neither
of these cohorts yielded a significant correlation of PH-
LPL activity with age.
The finding of lower PH-LPL activities in our study co-
hort would suggest that this group is enriched in individu-
als who have reduced PH-LPL levels and would thereby
implicate a reduction in PH-LPL activity as an etiological
factor in CAD. This would most likely be on the basis of
the atherogenicity of the small dense LDL, low HDLc, ele-
vated plasma TGs, and prolonged post-prandial lipemia
accompanying depressed PH-LPL activities (1, 45, 46).
This conclusion is supported by several studies that showed
that men with hypoalphalipoproteinemia and mild hyper-
triglyceridemia have significantly enhanced postprandial
lipemia (46–48). Also, a preponderance of small, LDL
particles has been linked to increased risk of myocardial
infarction, and a dense and protein-rich LDL has proved
to be characteristic of patients with CAD (49–51).
Plasma total triglyceride was found to correlate nega-
tively with PH-LPL activity in our study cohort (Fig. 1A).
This finding is similar to that of previous studies (6, 14, 15,
17) and confirms this relationship in the largest cohort of
CAD patients examined to date. This relationship was
manifest by both the VLDL and IDL fractions. HDLc was
positively correlated with PH-LPL activity, again confirm-
ing and extending previous findings (6–8, 10, 11) to a
large cohort of CAD patients. These relationships in our
subjects are in accordance with the role of LPL in the me-
tabolism of the triglyceride-rich lipoproteins, and the
maintenance of HDL levels. LPL is located on the capil-
lary endothelium and is active in the lipolysis and removal
of the triglycerides in chylomicrons, VLDL, and IDL. A re-
duction in LPL activity would therefore result in an in-
crease in plasma TG, through slower TG hydrolysis, and a
decrease in HDL due to decline in the rate of surface
component influx into the HDL pool.
Apolipoprotein E is an important component of the
clearance pathways for triglyceride-rich lipoproteins,
through its participation in their uptake through a receptor-
mediated process. Three isoforms are common in humans
(E2,3,4) and are known to independently influence lipid
and lipoprotein levels (51). They are therefore an impor-
tant factor to consider in the evaluation of the impact of
other components of the same clearance pathway on lipid
and lipoprotein levels. In this context, a recent study in 52
healthy males (13) provides evidence that apoE may mod-
ulate the effect of variations of LPL activity on lipid and li-
poprotein levels. However, unexpectedly, this effect was













N291S: n (%) 14 (7.3%) 8 (4.5%) 5 (2.8%) 5 (2.8%) 0.022
D9N: n (%) 9 (4.7%) 6 (3.4%) 5 (2.8%) 4 (2.2%) 0.17
N291S1D9N: n (%) 23 (12.0%) 14 (7.8%) 10 (5.0%) 9 (5.0%) 0.006
S447X: n (%) 22 (11.5%) 25 (14%) 31 (16.5%) 33 (18.3%) 0.047
a Quartile 1: LPL activity <77 mU/ml.
b Quartile 2: LPL activity 78–103 mU/ml.
c Quartile 3: LPL activity 104–132 mU/ml.
d Quartile 4: LPL activity >133 mU/ml.
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limited to carriers of the E2 isoform (E2/2 and E2/3; n 5
12), which showed statistically significant correlations be-
tween PH-LPL, and VLDL and HDL levels. No correla-
tions reached significance in the other two divisions, E3/3
(n 5 29) and E3/4, E4/4 (n 5 11). We have therefore
also studied the impact of apoE isoforms on PH-LPL rela-
tionships in our cohort of males and found no specific ef-
fect of the E2 isoform (Table 6). In fact, the association
between PH-LPL and TGs was weakest in the E2/2 1 E2/3
grouping; this is in direct contrast to the previous study
(13). All three genotype categories showed statistically sig-
nificant relationships, with the E3/3 division in particular,
paralleling the associations of the total subject cohort, by
yielding highly significant (P 5 ,0.001) relationships with
plasma–TG, LDLc, and HDLc. These data contradict
prior findings and, originating from a much larger co-
hort, suggest that the apoE polymorphism is of minor im-
portance in assessing the relationships between PH-LPL
activity and plasma lipid and lipoprotein levels.
We have shown here that CAD subjects in the REGRESS
study have a lower PH-LPL level than normal subjects. In
an attempt to characterize the factors determining the
lower level in these subjects, we determined their carrier
frequency for LPL variants known to be associated with
lower catalytic activities. Only two previously reported
functional variants, D9N and N291S, were detected in this
cohort, clearly indicating that no other additional muta-
tions in the LPL gene are likely to contribute to lowered
LPL activity levels in the Dutch population. The contribu-
tion of these variants to the depression of PH-LPL levels
was evident in comparisons of their carrier frequencies
in the lowest versus the highest quartile divisions of the
REGRESS cohort. Both variants were detected at an in-
creased prevalence in the former division, where a joint
carrier frequency of 12.0% was found. This is more than
double that of the 5.0% found in the upper quartile divi-
sion. Clearly, while these variants contribute significantly
to the etiology of the lower PH-LPL levels in this division,
other factors must be involved. The identity of these fac-
tors is undetermined as likely candidates such as age, BMI,
and beta-blockers did not differ significantly among the
quartile divisions.
Several studies examining the relationships between LPL
gene variants and lipid and lipoprotein levels in humans
(16, 32, 52–57) have provided direct and indirect evidence
that the S447X variant is associated with an increase in LPL
catalytic activity which manifests with lower plasma TGs and
higher HDLc levels in carriers of this variant. Based on
these data, the frequency of carrier status for the S447X
variant was predicted to be elevated in subjects in the upper
quartile of PH-LPL activities. This prediction was validated
as the carrier frequency of 18.3% (n 5 179) was signifi-
cantly elevated (P 5 0.006) above the 11.5% recorded for
individuals (n 5 191) in the lowest quartile of PH-LPL ac-
tivities. These data thus significantly strengthen the in vivo
evidence that the S447X variant manifests with a higher cat-
alytic activity when compared to wild type LPL. In vitro data
supporting this hypothesis have been sought in several mu-
tagenesis and transfection systems (26, 58–60) but thus far,
little difference has been discovered between the func-
tional activities of this variant and wild type LPL which may
point to a selective mechanism for the in vivo effect.
In conclusion, this study demonstrates that post-hep-
arin plasma LPL activity is an important determinant of
lipid and lipoprotein levels in humans, relatively indepen-
dent of secondary factors such as age and BMI. In addi-
tion, the REGRESS study provides evidence that low PH-
LPL activity is a risk factor for CAD and that common
mutations in the LPL gene can contribute to this risk
through their impact on the variation of PH-LPL levels in
these patients.
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